메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 17, 2009, Pages 2766-2771
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer
Author keywords

[No Author keywords available]
Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; CANCER GROWTH; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME;
EID: 67649965349     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.9159     Document Type: Article
Times cited : (93)
References (30)
  • 1
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, DeWit R, Berry W, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    DeWit, R.2    Berry, W.3
  • 2
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.A.3
  • 4
    • 0038514138 scopus 로고    scopus 로고
    • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    • Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 1232-1237
    • Halabi, S.1    Small, E.J.2    Kantoff, P.W.3
  • 5
    • 0032747375 scopus 로고    scopus 로고
    • Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
    • Bubley G, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 3461-3467
    • Bubley, G.1    Carducci, M.2    Dahut, W.3
  • 6
    • 41949104346 scopus 로고    scopus 로고
    • Design and endpoints of clinical trials for Patients with Progressive Prostate Cancer and Castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2)
    • Scher HI, Halabi S, Tannock I, et al: Design and endpoints of clinical trials for Patients with Progressive Prostate Cancer and Castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2). J Clin Oncol 26:1148-1159, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1148-1159
    • Scher, H.I.1    Halabi, S.2    Tannock, I.3
  • 7
    • 0032784113 scopus 로고    scopus 로고
    • Hydro-cortisone with or without mitoxantrone in men with hormone refractory prostate cancer: The results of CALGB 9182
    • Kantoff PW, Halabi S, Conaway M, et al: Hydro-cortisone with or without mitoxantrone in men with hormone refractory prostate cancer: The results of CALGB 9182. J Clin Oncol 17:2506-2513, 1999
    • (1999) J Clin Oncol , vol.17 , pp. 2506-2513
    • Kantoff, P.W.1    Halabi, S.2    Conaway, M.3
  • 8
    • 0034651802 scopus 로고    scopus 로고
    • A randomized study comparing standard vs. moderately high dose megestrol acetate in advanced prostate cancer: CALGB Study 9181
    • Dawson NA, Conaway M, Halabi S, et al: A randomized study comparing standard vs. moderately high dose megestrol acetate in advanced prostate cancer: CALGB Study 9181. Cancer 88:825-834, 2000
    • (2000) Cancer , vol.88 , pp. 825-834
    • Dawson, N.A.1    Conaway, M.2    Halabi, S.3
  • 9
    • 0035340275 scopus 로고    scopus 로고
    • Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780
    • Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. J Clin Oncol 19:2509-2516, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 2509-2516
    • Savarese, D.M.1    Halabi, S.2    Hars, V.3
  • 10
    • 0037102220 scopus 로고    scopus 로고
    • A randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159 (CALGB 9480)
    • Small EJ, Halabi S, Ratain MJ, et al: A randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159 (CALGB 9480). J Clin Oncol 20:3369-3375, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 3369-3375
    • Small, E.J.1    Halabi, S.2    Ratain, M.J.3
  • 11
    • 0036468760 scopus 로고    scopus 로고
    • Higher doses of mitoxantrone among men with hormone refractory prostate cancer: A Cancer and Leukemia Group B study
    • Levine EG, Halabi S, Roberts JD, et al: Higher doses of mitoxantrone among men with hormone refractory prostate cancer: A Cancer and Leukemia Group B study. Cancer 94:665-672, 2002
    • (2002) Cancer , vol.94 , pp. 665-672
    • Levine, E.G.1    Halabi, S.2    Roberts, J.D.3
  • 12
    • 0344236282 scopus 로고    scopus 로고
    • A phase II study of estramustine, docetaxel and carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813
    • Oh WK, Halabi S, Kelly WK, et al: A phase II study of estramustine, docetaxel and carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813. Cancer 98:2592-2598, 2003
    • (2003) Cancer , vol.98 , pp. 2592-2598
    • Oh, W.K.1    Halabi, S.2    Kelly, W.K.3
  • 13
    • 0346880557 scopus 로고    scopus 로고
    • The use of bevacizumab (B) and docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006
    • abstr 1578
    • Picus J, Halabi S, Rini B, et al: The use of bevacizumab (B) and docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22:393a, 2003 (abstr 1578)
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Picus, J.1    Halabi, S.2    Rini, B.3
  • 14
    • 1842457650 scopus 로고    scopus 로고
    • A Phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583
    • Small EJ, Halabi S, Dawson N, et al: A Phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583. J Clin Oncol 22:1025-1033, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1025-1033
    • Small, E.J.1    Halabi, S.2    Dawson, N.3
  • 15
    • 58149192808 scopus 로고    scopus 로고
    • A phase II study of estramustine, docetaxel and exisulind in patients with hormone-refractory prostate cancer (HRPC): Results of Cancer and Leukemia Group B (CALGB) 90004
    • Dawson NA, Halabi S, Ou SS, et al: A phase II study of estramustine, docetaxel and exisulind in patients with hormone-refractory prostate cancer (HRPC): Results of Cancer and Leukemia Group B (CALGB) 90004. Clin Genitourin Cancer 6:110-116, 2008
    • (2008) Clin Genitourin Cancer , vol.6 , pp. 110-116
    • Dawson, N.A.1    Halabi, S.2    Ou, S.S.3
  • 17
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 18
    • 0000336139 scopus 로고
    • Regression models and life tables
    • Cox DR: Regression models and life tables. J R Stat Soc B 74:187-220, 1972
    • (1972) J R Stat Soc B , vol.74 , pp. 187-220
    • Cox, D.R.1
  • 19
    • 35948933892 scopus 로고    scopus 로고
    • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer (HRPC)
    • Armstrong AJ, Garrett-Mayer ES, Ou Yang Y, et al: A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer (HRPC). Clin Cancer Res 13:6396-6403, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 6396-6403
    • Armstrong, A.J.1    Garrett-Mayer, E.S.2    Ou Yang, Y.3
  • 20
    • 0010394791 scopus 로고    scopus 로고
    • A test for partial correlation with censored astronomical data
    • Akritas MG, Siebert J: A test for partial correlation with censored astronomical data. Mon Not R Astron Soc 278:919-924, 1996
    • (1996) Mon Not R Astron Soc , vol.278 , pp. 919-924
    • Akritas, M.G.1    Siebert, J.2
  • 21
    • 84923818429 scopus 로고
    • Better bootstrap confidence intervals (with discussion)
    • Efron B: Better bootstrap confidence intervals (with discussion). J Am Stat Assoc 82:171, 1987
    • (1987) J Am Stat Assoc , vol.82 , pp. 171
    • Efron, B.1
  • 22
    • 33646443546 scopus 로고    scopus 로고
    • Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    • Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521, 2006
    • (2006) J Natl Cancer Inst , vol.98 , pp. 516-521
    • Petrylak, D.P.1    Ankerst, D.P.2    Jiang, C.S.3
  • 23
    • 34548537940 scopus 로고    scopus 로고
    • PSA and pain surrogacy analysis in men with metastatic hormone-refractory prostate cancer (HRPC)
    • Armstrong AJ, Ou Yang Y, Garrett-Mayer ES, et al: PSA and pain surrogacy analysis in men with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 25:3965-3970, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 3965-3970
    • Armstrong, A.J.1    Ou Yang, Y.2    Garrett-Mayer, E.S.3
  • 24
    • 40749122148 scopus 로고    scopus 로고
    • A phase II clinical trial of sorafenib in androgen-independent prostate cancer
    • Dahut WL, Scripture C, Posadas E, et al: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14:209-214, 2008
    • (2008) Clin Cancer Res , vol.14 , pp. 209-214
    • Dahut, W.L.1    Scripture, C.2    Posadas, E.3
  • 25
    • 9444227104 scopus 로고    scopus 로고
    • Randomized phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer
    • Abratt RP, Brune D, Dimopoulos MA, et al: Randomized phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15:1613-1621, 2004
    • (2004) Ann Oncol , vol.15 , pp. 1613-1621
    • Abratt, R.P.1    Brune, D.2    Dimopoulos, M.A.3
  • 26
    • 35648968713 scopus 로고    scopus 로고
    • A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
    • Carducci MA, Saad F, Abrahamsson PA, et al: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959-1966, 2007
    • (2007) Cancer , vol.110 , pp. 1959-1966
    • Carducci, M.A.1    Saad, F.2    Abrahamsson, P.A.3
  • 27
    • 28944449952 scopus 로고    scopus 로고
    • A phase II trial of oral trimethylcolchicinic acid with hormone refractory prostate cancer
    • Brockstein BE, Shepard DR, Kugler JW, et al: A phase II trial of oral trimethylcolchicinic acid with hormone refractory prostate cancer. Prostate J 1:195-202, 1999
    • (1999) Prostate J , vol.1 , pp. 195-202
    • Brockstein, B.E.1    Shepard, D.R.2    Kugler, J.W.3
  • 28
    • 0030969232 scopus 로고    scopus 로고
    • The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints
    • Dawson NA, McLeod DG: The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints. Eur J Cancer 33:560-565, 1997
    • (1997) Eur J Cancer , vol.33 , pp. 560-565
    • Dawson, N.A.1    McLeod, D.G.2
  • 29
    • 45149113853 scopus 로고    scopus 로고
    • Pain predicts overall survival in men with metastatic castrate refractory prostate cancer (CRPC)
    • Halabi S, Vogelzang NJ, Kornblith AB, et al: Pain predicts overall survival in men with metastatic castrate refractory prostate cancer (CRPC). J Clin Oncol 26:2544-2549, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2544-2549
    • Halabi, S.1    Vogelzang, N.J.2    Kornblith, A.B.3
  • 30
    • 33947355892 scopus 로고    scopus 로고
    • The association between measures of progression and survival in castrate-metastatic prostate cancer
    • Scher HI, Warren M, Heller G: The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13:1488-1492, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 1488-1492
    • Scher, H.I.1    Warren, M.2    Heller, G.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.